@skorusARK Possibly. https://t.co/CmtQ8BF8cP
RT @Science_Open: @DovePress NEW article in the 'Drug Design, Development and Therapy' #ScienceOpen Collection by @DovePress: ‘The developm…
@DovePress NEW article in the 'Drug Design, Development and Therapy' #ScienceOpen Collection by @DovePress: ‘The development of an oral GLP-1 receptor agonist for the management of #Type2 #diabetes: evidence to date’ https://t.co/Ap4m3Kx2Pr #DiabetesAware
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
RT @AbdTahrani: Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kaml…
Our review article re the development of Oral GLP-1 agonists for T2 #diabetes ; with @Nirantharakumar and colleagues. @kamleshkhunti @AmarPut @drpatrickholmes @PokrajacAna @BHPComms @BHPClinAc @IMSR_UoB @UoB_IAHR @hazlehurst_j @drpunith https://t.co/watX